Home>>Lipids>> Reactive O2/N2 Pathways>>8-iso Prostaglandin E2

8-iso Prostaglandin E2 Sale

(Synonyms: iPE2-III) 目录号 : GC41425

An isoprostane with renal vasoconstrictor and anti-platelet aggregation activity

8-iso Prostaglandin E2 Chemical Structure

Cas No.:27415-25-4

规格 价格 库存 购买数量
500μg
¥754.00
现货
1mg
¥1,439.00
现货
5mg
¥6,030.00
现货
10mg
¥10,552.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

8-iso PGE2 is one of several isoprostanes produced from arachidonic acid during lipid peroxidation. It is a potent renal vasoconstrictor in the rat. 8-iso PGE2 inhibits U-46619 or I-BOP-induced platelet aggregation with IC50 values of 0.5 and 5 µM, respectively. When infused into the renal artery of the rat at a concentration of 4 µg/kg/min, 8-iso PGE2 decreases the GFR and renal plasma flow by 80% without affecting blood pressure.

Chemical Properties

Cas No. 27415-25-4 SDF
别名 iPE2-III
Canonical SMILES O[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H](C/C=C\CCCC(O)=O)C(C1)=O
分子式 C20H32O5 分子量 352.5
溶解度 DMF: >100 mg/ml (from PGE2),DMSO: >100 mg/ml (from PGE2),Ethanol: >100 mg/ml (from PGE2),PBS pH 7.2: >5 mg/ml (from PGE2) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.8369 mL 14.1844 mL 28.3688 mL
5 mM 0.5674 mL 2.8369 mL 5.6738 mL
10 mM 0.2837 mL 1.4184 mL 2.8369 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Effect of the isoprostanes, 8-iso Prostaglandin E2 and 8-iso prostaglandin F2 alpha on the rabbit lung in vivo

Prostaglandins 1997 Feb;53(2):69-82.PMID:9112286DOI:10.1016/s0090-6980(97)00004-x.

8-Iso-prostaglandin (PG)E2 and 8-iso-PGF2 alpha are members of the isoprostane class of prostanoids which are formed by free radical mediated oxidation of arachidonic acid. Both E2- and F2-isoprostanes are potent vasoconstrictors and are believed to act through the prostanoid TP-receptors or a closely related receptor. In lightly anaesthetised, spontaneously breathing rabbits, aerosolised administration of histamine (1.25-40 mg ml-1, n = 8) caused a modest dose-dependent increase in total lung resistance (RL) and a concomitant fall in dynamic lung compliance (CL dyn). Aerosolised methacholine (0.625-20 mg ml-1, n = 6) caused considerable bronchoconstriction, with a dose-dependent increase in RL, and a corresponding fall in CL dyn. In contrast, intratracheal administration of either 8-iso PGE2 or 8-iso-PGF2 alpha (1 ng ml(-1)-100 micrograms ml-1, n = 8) had no significant effect on lung function. The TP-receptor agonist, U-46619, was similarly inactive in this model when given by aerosol. Intravenous administration of histamine or 8-iso PGF2 omega had no significant effect on the lung indices, RL and CL dyn, or on the pulmonary and systemic vasculature (n = 4 per drug group). 8-Iso-PGE2 caused a concentration-dependent decrease in the right ventricular systolic pressure from 3 nmol kg-1 to 100 nmol kg-1 (n = 43, p < 0.05), but showed no other activity. In contrast, U-46619 given intravenously caused an increase in transpulmonary pressure (n = 4, p < 0.05), but had no effect on airflow. At higher doses, it did cause a significant drop in both systemic and right ventricular systolic pressures (n = 4, p < 0.05), which were probably due to an interaction with platelets. The isoprostanes had no effect on the rabbit airway up to a concentration of 3 microM. In contrast, 3 microM U-46619 caused a modest contraction of tracheal smooth muscle, whilst 3 microM methacholine was at least five-fold more potent in contracting the same tissues. We conclude that the aerosolised isoprostanes are not broncho-constricting agents in the rabbit in vivo.

Effect of latanoprost or 8-iso Prostaglandin E2 alone and in combination on intraocular pressure in glaucomatous monkey eyes

Arch Ophthalmol 2000 Jan;118(1):74-7.PMID:10636418DOI:10.1001/archopht.118.1.74.

Objective: To evaluate the possible additivity of the effects of latanoprost and 8-iso Prostaglandin E2 (8-iso PGE2) on intraocular pressure (IOP) in monkey eyes with laser-induced glaucoma. Methods: The IOP was measured hourly for 6 hours beginning at 9:30 AM on day 1 (baseline day), days 6 and 7 (single-agent therapy), and days 13 and 14 (combination therapy with both agents). Following 1 day of baseline measurement, 4 monkeys with unilateral glaucoma received monotherapy) twice daily with either 1 drop of 0.005% latanoprost, or 0.1% 8-iso PGE2, 25 microL, at 9:30 AM and 3:30 PM from days 2 through 7. From days 8 through 14, both agents were applied twice daily 5 minutes apart. Results: The maximum reduction of IOP (mean +/- SEM) was 8.8 +/- 1.9 mmHg (26%) (P<.05) with latanoprost alone and 6.5 +/- 1.0 mmHg (21%) (P<.0l) with 8-iso PGE2 alone, 2 hours after the morning dosing on day 7. A further reduction of IOP of 4.0 +/- 0.6 mm Hg was produced when 8-iso PGE2 was added to latanoprost and of 3.0 +/- 0.7 mm Hg was produced when latanoprost was added to 8-iso PGE2 on day 13 before the morning dosing. Combination therapy with both agents caused maximum IOP reductions from baseline of 11.3 +/- 3.0 mm Hg (33%) (P<.05) (latanoprost with 8-iso PGE2 added) and of 9.8 +/- 1.3 mm Hg (31%) (P<.01) (8-iso PGE2 with latanoprost added) on day 14. Conclusion: Latanoprost and 8-iso PGE2 have an additive effect on IOP in glaucomatous monkey eyes. Clinical relevance: At least 50% of patients are treated with more than 1 ocular hypotensive medication. Thus, the determination of the additive effects on IOP of glaucoma medications will help to define optimum treatment regimens.

Effect of 8-iso Prostaglandin E2 on aqueous humor dynamics in monkeys

Arch Ophthalmol 1998 Sep;116(9):1213-6.PMID:9747682DOI:10.1001/archopht.116.9.1213.

Objective: To evaluate the effects of 8-iso Prostaglandin E2 (8-iso PGE2; prosta-5,13-dien-1-oic acid,11,15-dihydroxy-9-oxo-,[5Z,8beta-11X,13E,15 S]-) on the intraocular pressure (IOP), outflow facility, and aqueous humor flow rates in normal monkeys and monkeys with glaucoma. Methods: The IOP was measured before and as long as 6 hours after the topical application of 8-iso PGE2 to 1 eye of 6 normal monkeys and to the glaucomatous eye of 8 monkeys with unilateral laser-induced glaucoma. The pupil diameter was measured at the same times as the IOP measurements in the normal monkeys. Tonographic outflow facility and fluorophotometric flow rates of aqueous humor were measured in 6 normal monkeys before and after drug treatment. Results: In normal monkeys, a single dose of 0.1% 8-iso PGE2 reduced (P<.01) the IOP for 4 hours in the treated eyes with a maximum (mean +/- SEM) reduction of 3.2 +/- 0.2 mm Hg, compared with the contralateral control eyes. The pupil size was smaller (P<.01) in the treated eyes by as much as 1.0 +/- 0.2 mm for 4 hours. In 8 glaucomatous monkey eyes, the application of 0.05% and 0.1% 8-iso PGE2 reduced the IOP (P<.01) for as long as 2 and 5 hours, respectively. The maximum reduction in the IOP was 4.6 +/- 0.8 mm Hg (0.05%) and 6.0 +/- 0.8 mm Hg (0.1%) compared with baseline measurements. The magnitude and duration of the ocular hypotensive effect were enhanced with twice-a-day administration for 5 consecutive days. Outflow facility in normal monkey eyes was increased (P<.05) by 48% in the treated eyes, and aqueous humor flow was unchanged (P>.10), compared with vehicle-treated contralateral control eyes. Mild eyelid edema, conjunctival edema, hyperemia, and discharge appeared in some eyes treated with the 0.1% drug concentration. Conclusions: The use of 8-iso PGE2 reduces the IOP in both normal and glaucomatous monkey eyes. An increase in outflow facility appears to account for most of the IOP reduction in normal monkeys. Clinical relevance: The application of 8-iso PGE2 may have potential for the treatment of glaucoma as an outflow facility-increasing drug.

Effect of pilocarpine 4% in combination with latanoprost 0.005% or 8-iso Prostaglandin E2 0.1% on intraocular pressure in laser-induced glaucomatous monkey eyes

J Glaucoma 2001 Jun;10(3):215-9.PMID:11442186DOI:10.1097/00061198-200106000-00013.

Purpose: To compare the effect of pilocarpine, an agent that reduces uveoscleral outflow, on the ocular hypotensive efficacy of latanoprost and 8-iso Prostaglandin E2 (PGE2). Methods: Each of the two treatment groups was composed of the same eight monkeys with unilateral laser-induced glaucoma. Intraocular pressure (IOP) was measured hourly for 6 hours beginning at 9:00 AM on the baseline day (Thursday before treatment week) and on treatment days 1, 3, and 5 (Monday, Wednesday, and Friday). On all five treatment days, one drop of pilocarpine 4% was administered at 9:00 AM and 3:00 PM and one drop of latanoprost 0.005% or 25 microL of 8-iso PGE2 0.1% was administered at 10:00 AM and 4:00 PM. Results: One hour after pilocarpine instillation on day 1, the reduction of IOP was similar (P > 0.90) in both treatment groups, 7.6 +/- 1.1 mm Hg (mean +/- standard error of the mean ) in the latanoprost group and 7.4 +/- 0.8 mm Hg in the 8-iso PGE2 group. However, the IOP effects of the two treatment groups became significantly different (P < 0.05) beginning 2 hours after dosing with latanoprost or 8-iso PGE, on day 1. A difference (P < 0.05) between the two groups persisted at all subsequent measurements. The reduction of IOP lessened with repeated dosing in the latanoprost and 8-iso PGE2 groups. Three hours after dosing with pilocarpine and two hours after dosing with the prostanoids, the IOP reduction was 8.3 +/- 0.9 mm Hg in the latanoprost group and 9.9 +/- 0.6 mm Hg in the 8-iso PGE2 group on day 1, and 2.1 +/- 1.0 mm Hg in the latanoprost group and 7.3 +/- 0.9 mm Hg in the 8-iso PGE1 group on day 5. Conclusions: The smaller reductions in IOP with pilocarpine and latanoprost than with pilocarpine and 8-iso PGE2 show that pilocarpine blocks much more of the ocular hypotensive effect of latanoprost than of 8-iso PGE2. The results also indicate that pilocarpine and latanoprost are mutually antagonistic. Enhancement of uveoscleral outflow appears to account for most of the ocular hypotensive effect of latanoprost and for much less of the ocular hypotensive effect of 8-iso Prostaglandin E2.